Targeting Th17 cytokines such as IL-6, IL-17, and IL-23 is an effective strategy in rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD) (23–26). Here, IL6 is linked to rheumatoid arthritis.